Research Focus

Medicine; Research Project Associate

Recent additions – View all

1. Olaparib and durvalumab in patients with DNA damage repair alterations and biochemically recurrent prostate cancer

   Journal Article

   Autio, K. A.; McHugh, D. J.; Rathkopf, D. E.; Xiao, H.; Merugu, S.; Wong, P.; Jan, M.; Dorff, T. B.; Heath, E. I.; Scher, H. I.
   Journal of Immunotherapy and Precision Oncology (2025)

   Fulltext@MSK | Save
2. A phase Ib/II study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer (mCRPC) and no mutations in DNA damage repair (DDR)

   Meeting Abstract

   Autio, K. A.; Kyriakopoulos, C.; Xiao, H.; Emamekhoo, H.; Danila, D. C.; Devitt, M. E.; Riedel, E.; Jan, M.; Scher, H. I.
   Journal of Clinical Oncology (2023)

   Fulltext@MSK | Save